# Viewpoint Molecular Targeting

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/viewpoint-molecular-targeting

- Industry: Pharmaceuticals
- Headquarters: Coralville, US
- Website: www.viewpointmt.com
- Total disclosed funding: $13M
- Latest round: Series A (Nov 20, 2020)
- Investors on record: 1

## About

Based in Iowa, US, and founded in 2008, Viewpoint Molecular Targeting, Inc., operates as a developer of pharmaceutical drugs and therapies intended for diagnostic imaging and therapy for cancer, with a focus on metastatic melanoma. In January 2021, Viewpoint Molecular Targeting, Inc. received USD 5 million in grant funding from the National Cancer Institute. As of 2023, the company partners with companies like Eichrom Technologies LLC., Pepscan Therapeutics B.V., SpectronRx, and many more.

The company offers various pharmaceutical solutions that include alpha-particle theranostics used to reveal cancer cells in the body. The company’s targeted alpha therapies include pipelines like Pb-203, Pb-212, bismuth-212, polonium-212, and thallium-208, which help cancer-killing alpha-particle radiation be used for energy, medical, national security, and basic research.

The company's product targets a cell surface receptor that is found on the cell surface of metastatic melanoma cells and can be used to determine the location and extent of cancerous tumours in the body, enabling health professionals to direct a lethal dose of radiation precisely to cancer cells in the body.

## Funding rounds

- Series A, Nov 20, 2020, $13M — Next Level Ventures

## Investors

- Next Level Ventures (https://capitalatlas.ai/funds/next-level-ventures) — Series A